Tempest Therapeutics, Inc. (TPST): Nasdaq/NYSE listing notice — Tempest Therapeutics receives Nasdaq bid price deficiency notice; stock below $1.00

Tempest Therapeutics, Inc.

Received Nasdaq deficiency letter on Dec 27, 2024 for bid price below $1.00 for 30 consecutive business days.
Has 180 calendar days (until June 25, 2025) to regain compliance by closing at $1.00+ for 10 consecutive days.
Stockholders approved a reverse stock split (range 1:2 to 1:15) on Dec 3, 2024; Board may implement to cure deficiency.
If not compliant by June 25, 2025, may qualify for an additional 180-day period if other listing standards are met.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.97

Tempest Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

December 27, 2024, Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company’s common stock on the Nasdaq Stock Market. In accordance with

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Tempest Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-287170

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.